Covalent polar lipid conjugates with biologically active compounds for use in salves

Abstract

This invention herein describes a method of facilitating the entry of drugs into cells and tissues at pharmokinetically useful levels and also a method of targeting drugs to specific organelles within the cell. This polar lipid/drug conjugate targeting invention embodies an advance over other drug targeting methods because through this method, intracellular drug concentrations may reach levels which are orders of magnitude higher than those achieved otherwise. Furthermore, it refines the drug delivery process by allowing therapeutic agents to be directed to certain intracellular structures. This technology is appropriate for use with antiproliferative, antibiotic, antimycotic, antiviral and antineoplastic drugs, in particular in combination with a multiplicity of other emollients and agents to make up topically-active substances such as salves, for rapid and efficient introduction of such agents through the epidermis for treatment of skin diseases and other disorders.

What is claimed is:  
     
         1 . A pharmaceutical composition comprising a corticosteroid drug, a polar lipid carrier, two linker functional groups and a spacer, wherein the spacer has a first end and a second end and wherein the polar lipid is attached to the first end of the spacer through a first linker functional group and the drug is attached to the second end of the spacer through a second linker functional group, the composition further comprising a medicinal ointment or salve.  
     
     
         2 . The pharmaceutical composition of  claim 1  wherein the drug is selected from the group consisting of cortisone, cortisol, hydrocortisone, prednisone, fluorinated corticosteroids, dexamethasone, alcloethasone, fluoroandrenolide and mometasone.  
     
     
         3 . A pharmaceutical composition according to  claim 1  wherein the spacer allows the drug to act without being released at an intracellular site and wherein the first linker functional group attached to the first end of the spacer is strong and the second linker functional group attached to the second end of the spacer is weak.  
     
     
         4 . A pharmaceutical composition according to  claim 1  wherein the spacer allows the facilitated hydrolytic release of the drug at an intracellular site and wherein the first linker functional group attached to the first end of the spacer is strong and the second linker functional group attached to the second end of the spacer is weak.  
     
     
         5 . A pharmaceutical composition according to  claim 1  wherein the spacer allows the facilitated enzymatic release of the drug at an intracellular site and wherein the first linker functional group attached to the first end of the spacer is strong and the second linker functional group attached to the second end of the spacer is weak.  
     
     
         6 . A pharmaceutical composition according to  claim 1  wherein the polar lipid is acyl carnitine, acylated carnitine, sphingosine, ceramide, phosphatidyl choline, phosphatidyl glycerol, phosphatidyl ethanolamine, phospliatidyl inositol, phosphatidyl serine, cardiolipin or phosphatidic acid.  
     
     
         7 . A pharmaceutical composition comprising a corticosteroid drug having a first functional linker group, and a polar lipid carrier having a second functional linker group, wherein the drug is covalently linked to the polar lipid carrier by a chemical bond between the first and second functional linker groups, the composition further comprising a medicinal ointment or salve.  
     
     
         8 . A pharmaceutical composition according to  claim 7  wherein the first functional linker group is a hydroxyl group, a primary or secondary amino group, a phosphate group or substituted derivatives thereof or a carboxylic acid group.  
     
     
         9 . A pharmaceutical composition according to  claim 7  wherein the second functional linker group is a hydroxyl group, a primary or secondary amino group, a phosphate group or substituted derivatives thereof or a carboxylic acid group.  
     
     
         10 . A pharmaceutical composition according to  claim 7  wherein the polar lipid is acyl carnitine, acylated carnitine, sphingosine, ceramide, phosphatidyl choline, phosphatidyl glycerol, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine, cardiolipin or phosphatidic acid.  
     
     
         11 . The pharmaceutical composition of  claim 7  wherein the drug is selected from the group consisting of cortisone, cortisol, hydrocortisone, prednisone, fluorinated corticosteroids, dexamethasone, alcloethasone, fluoroandrenolide and mometasone.  
     
     
         12 . A method for treating a pathological condition or disease state in cells, tissues or organs in an animal, the method comprising the step of administering to the animal a pharmaceutical composition of  claim 1  in an acceptable carrier or formulation and in an amount sufficient to alleviate the pathological condition or disease state in the animal.  
     
     
         13 . A method for treating a pathological condition or disease state in skin of an animal, wherein the pathological condition or disease state results from an abnormal proliferation of cells in the animal, the method comprising the step of administering to the animal a pharmaceutical composition according to  claim 1  in an acceptable carrier or formulation and in an amount sufficient to alleviate the pathological condition or disease state in the animal.  
     
     
         14 . The method of  claim 12  wherein the animal is a human.  
     
     
         15 . A method for treating a pathological condition or disease state in cells, tissues or organs in an animal, the method comprising administering to the animal a pharmaceutical composition according to  claim 7  in an acceptable carrier or formulation and in an amount sufficient to alleviate the pathological condition or disease state in the animal.  
     
     
         16 . A method for treating a pathological condition or disease state in skin of an animal, wherein the pathological condition or disease state results from an abnormal proliferation of cells in the animal, the method comprising the step of administering to an animal a pharmaceutical composition according to  claim 7  in an acceptable carrier or formulation and in an amount sufficient to alleviate the pathological condition or disease state in the animal.  
     
     
         17 . The method of  claim 15  wherein the animal is a human.  
     
     
         18 . A pharmaceutical composition according to  claim 1  wherein the spacer is a peptide of formula (amino acid) n , wherein n is an integer between 2 and 25, and the peptide comprises a polymer of one or more amino acids.  
     
     
         19 . The method of  claim 12 , wherein the disease state is a skin disease.  
     
     
         20 . A pharmaceutical composition according to  claim 1  wherein the spacer is a cleavable linker moiety that is specifically, cleaved inside a mammalian skin cell.  
     
     
         21 . The pharmaceutical composition of  claim 20  wherein the cleavable linker moiety is chemically cleaved inside a mammalian skin cell.  
     
     
         22 . The pharmaceutical composition of  claim 20  wherein the cleavable linker moiety is a substrate for a protein having an enzymatic activity said protein being specifically expressed in a mammalian skin cell.  
     
     
         23 . A pharmaceutical composition according to  claim 7  wherein the chemical bond linker the polar lipid and the corticosteroid drug is specifically cleaved inside a mammalian skin cell.  
     
     
         24 . The pharmaceutical composition of  claim 23  wherein the chemical bond is chemically cleaved inside a mammalian skin cell.  
     
     
         25 . The pharmaceutical composition of  claim 23  wherein the chemical bond is a substrate for a protein having an enzymatic activity said protein being specifically expressed in a mammalian skin cell.  
     
     
         26 . The method of  claim 16  wherein the animal is a human.  
     
     
         27 . The method of  claim 13 , wherein the disease state is a skin disease.  
     
     
         28 . The method of  claim 15 , wherein the disease state is a skin disease.  
     
     
         29 . The method of  claim 16 , wherein the disease state is a skin disease.  
     
     
         30 . The method of  claim 13 , wherein the animal is a human.